“The study is really interesting and provocative,” said David Fisher, a cancer biologist focusing on melanoma at Massachusetts General Hospital in Boston who was not involved in the work. “It underlines even more than what we knew previously: that melanin biochemistry is a two-edged sword—there are benefits and liabilities.”